Abbott Q3 & 9M 2025 Results — ABT Earnings

Abbott posted double-digit EPS growth alongside higher sales in both the third quarter and the first nine months of 2025. For the nine months ended September 30, 2025, consolidated revenue totaled $32,869 million, with international sales accounting for 61.2% ($20,126 million) of the total. The contribution mix underscores the company's global footprint and the outsized role of non-U.S. markets in 2025 results. The firm cites strength across several franchises. Diagnostics contributed $11,369 million for the nine-month period, while Nutritionals showed roughly $15,712 million (partial totals reported), reflecting continued demand in pediatric and adult nutrition businesses. Established Pharmaceutical Products totaled $4,154 million for the period, driven by activity in key emerging markets.

Abbott's results reflect a multi-segment business where different units drive growth. Nutritionals and Diagnostics accounted for large portions of nine-month revenue, while Medical Devices showed solid U.S. contributions (U.S. medical devices revenue of $5,448 million for the nine months, including Diabetes Care sales of about $2,057 million). Strategic product areas cited in company filings as material to future performance include FreeStyle Libre continuous glucose monitoring in Diabetes Care, structural heart therapies (MitraClip, Navitor), molecular diagnostics (Alinity m/m2000 systems), and advanced device platforms such as Aveir leadless pacemakers and ICD technologies. These product lines are identified in filings as focal points for innovation and near-term growth, though filings also note that no single patent or product is solely material to the company as a whole.

Abbott's 2025 filings outline several risks investors should weigh. Regulatory uncertainty (including approvals and reimbursement pressures), ongoing legal and environmental compliance matters, macroeconomic exposure from currency and inflation, supply-chain constraints, and cybersecurity threats are highlighted as key risk areas. Competition is intense across Diagnostics, Medical Devices and Nutritionals. Major peers in diagnostics and devices (as noted in filings) include Roche Diagnostics, Siemens Healthineers, Medtronic, Boston Scientific and Edwards Lifesciences; Nutritional competitors include Reckitt Benckiser and Nestlé Health Science. The company's own assessment points to an absence of a sustainable structural economic moat; advantages are described as execution-based (product innovation, installed systems and service relationships) rather than structural barriers to entry. This increases sensitivity to competitor product introductions, pricing pressure and regulatory shifts.

Investors focused on Abbott should weigh the combination of double-digit EPS growth and higher consolidated sales against the firm's risk profile and competitive pressures. The nine-month 2025 revenue mix—with roughly 61% international exposure—amplifies sensitivity to foreign exchange and ex-U.S. pricing/tender dynamics. Key watch items include regulatory outcomes for device and diagnostic filings, performance in Diabetes Care and Structural Heart franchises, and management commentary on margin trends and supply-chain costs in upcoming quarterly disclosures.